Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 32s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Teratogenic Effects Across Species: Insights from Animal Studies to Human Health Implications

Dr Ravi Dutt Sharma [1], Mr. Daniel Deepak Kumar[2]

[1]Assistant Professor in Biology, College of Engineering & Technical Vocational Education & Training, Fiji National University, Republic of Fiji.
Email ID : ravi.sharma@fnu.ac.fj
[2]Lecturer in Biology, College of Engineering & Technical Vocational Education & Training, Fiji National University, Republic of Fiji.
Email ID: Daniel.k@fnu.ac.fj

Cite this paper as: Dr Ravi Dutt Sharma , Mr. Daniel Deepak Kumar (2025) Teratogenic Effects Across Species: Insights from Animal Studies to Human Health Implications. *Journal of Neonatal Surgery*, 14 (32s), 5729-5741.

ABSTRACT

Teratogenicity refers to the ability of substances to cause developmental malformations in embryos or fetuses, posing significant challenges in pharmacology and toxicology, especially in the context of drug safety during pregnancy. Animal models have long been instrumental in studying the mechanisms of teratogenesis, providing insights into the molecular, genetic, and environmental factors that contribute to developmental defects. However, despite their utility, animal models have limitations due to species-specific differences in drug metabolism and development. Emerging technologies, including CRISPR gene-editing, nanotechnology, and organ-on-chip systems, offer promising alternatives that could enhance the accuracy of teratogenicity testing while reducing the ethical concerns associated with animal use. This paper explores the role of animal models in teratogenicity research, discusses the challenges of translating animal findings to human health implications, and highlights the potential of cutting- edge technologies to revolutionize the field, leading to better predictive accuracy and safer drug development

Keywords: Teratogenicity, Animal Models, CRISPR, Nanotechnology, Organ-on-chip

1. INTRODUCTION

Teratogenicity is the term used to describe the ability of certain substances, known as teratogens, to cause developmental malformations in embryos or fetuses. These malformations can affect the normal development of organs and tissues, leading to birth defects that may range from minor cosmetic abnormalities to severe structural and functional impairments. The impact of teratogenicity is particularly concerning in the fields of pharmacology and toxicology because many drugs, chemicals, and environmental exposures have the potential to disrupt fetal

development, especially when the fetus is most vulnerable during early stages of pregnancy. The safety of medications and environmental chemicals is paramount, particularly for pregnant women who may be unknowingly exposed to substances that can be harmful to the developing fetus. The importance of understanding and assessing the teratogenic potential of substances has grown as the number of prescription drugs, over-the-counter medications, and environmental pollutants in daily life increases. According to Briggs, Freeman, and Yaffe (2011), the potential risks posed by teratogens during pregnancy must be carefully evaluated to prevent congenital malformations and to ensure the health and well-being of both the mother and the child. The societal consequences of teratogenic exposure are immense, with congenital malformations contributing significantly to long-term healthcare burdens, especially in low- and middle-income countries. These birth defects often result in lifelong disability, requiring extensive medical treatment and support for affected individuals and their families. Gilbert-Barness (2008) further emphasizes the growing concern over the rise in congenital disorders linked to teratogenic exposures, making it a priority for both researchers and health policymakers to address this issue.

Table 1: Global Prevalence of Teratogenic Disorders

Region	Prevalence of Congenital Birth Defects	Key Disorders
Global	~1,573 per 100,000 live births	Neural tube defects, congenital heart defects, cleft lip/palate
North America	~1,500–2,000 per 100,000 live births	Neural tube defects, congenital heart defects, cleft lip/palate
Europe	~1,200–1,800 per 100,000 live births	Neural tube defects, Down syndrome, cleft lip/palate
Asia	~1,000–1,500 per 100,000 live births	Neural tube defects, congenital heart defects, cleft lip/palate
Africa	~1,500–2,000 per 100,000 live births	Neural tube defects, congenital heart defects, cleft lip/palate
South America	~1,200–1,800 per 100,000 live births	Neural tube defects, congenital heart defects, cleft lip/palate
Oceania	~1,800–2,500 per 100,000 live births	Neural tube defects, congenital heart defects, cleft lip/palate

Animal models have played a pivotal role in advancing our understanding of teratogenicity. The use of these models allows scientists to study the mechanisms of developmental toxicity in a controlled environment, something that would be impossible in human subjects due to ethical concerns and the complexity of human fetal development. Various animal species, including rodents, rabbits, and non-human primates, are frequently employed in teratogenicity studies. Rodents, particularly rats and mice, are favored due to their well-documented genetic characteristics and relatively short gestational periods, making them ideal for high-throughput screening of potential teratogens. Non-human primates, due to their closer genetic and physiological similarity to humans, provide the most reliable data for assessing the potential impacts of teratogens on human fetal development. Wells et al. (2005) discuss how these models have been instrumental in identifying the teratogenic effects of various pharmaceutical agents, chemicals, and environmental toxins. Additionally, the advent of CRISPR gene-editing and the development of transgenic animals have further advanced the accuracy and precision of animal models in teratogenicity research. These technologies allow researchers to manipulate specific genes that are suspected to play a role in susceptibility to teratogenic effects, offering a more targeted approach to understanding the underlying mechanisms of drug-induced developmental abnormalities (Wells et al., 1997). These models have not only contributed to scientific understanding but have also shaped the regulatory frameworks that govern drug safety. They provide critical data that inform the guidelines set forth by agencies such as the FDA and EMA to ensure that medications prescribed to pregnant women do not pose an undue risk to fetal development.



Figure 1: Flowchart of Teratogenic Risk Assessment Using Animal Models:

Illustrates the step-by-step process of assessing the teratogenic potential of substances, from animal testing and model selection to human health impact and regulatory actions. It emphasizes the progression of data analysis leading to human safety evaluations and guidelines.

This paper aims to explore the teratogenic effects observed across various species, with a particular focus on the translation of these animal study findings into human health implications. The goal is to critically examine the role of animal models in identifying teratogens and understanding the mechanisms through which they induce developmental abnormalities. By discussing the strengths and limitations of these models, the paper will highlight the challenges associated with translating findings from animal studies to human contexts. Furthermore, the ethical considerations surrounding the use of animals in teratogenicity research will be addressed, acknowledging the growing concern about the welfare of animals used in testing. In

light of these concerns, the paper will also discuss emerging alternatives, such as organ-on-chip systems and stem cell-based models, which aim to reduce the reliance on animal testing while improving the predictive accuracy of teratogenicity assessments (López-Rodríguez et al., 2018). These innovations represent a promising shift towards more ethical and human-relevant testing methodologies, which could potentially replace or complement traditional animal models in the future.

Teratogenic Mechanisms and Their Impact on Development

The molecular mechanisms underlying teratogenesis are multifaceted and involve various pathways that disrupt normal fetal development. One of the primary mechanisms is oxidative stress, which occurs when reactive oxygen species (ROS) are generated in excess. ROS can cause significant damage to cellular structures, including lipids, proteins, and DNA, leading to cell dysfunction, apoptosis, or necrosis. This oxidative damage is particularly important in the context of teratogenicity, as it can impair normal embryonic development and lead to congenital malformations. Substances like thalidomide and valproic acid, both of which have been shown to induce birth defects, exert their teratogenic effects through ROS-induced oxidative stress (Wells et al., 2005). Thalidomide, for instance, is known to cause limb malformations and other structural

defects by triggering excessive oxidative damage during critical stages of limb development. Similarly, valproic acid, a medication used primarily for epilepsy, has been associated with neural tube defects in human infants, which are believed to result, in part, from its ability to increase ROS levels in developing tissues (Szyf, 1985).

In addition to oxidative stress, epigenetic modifications play a crucial role in the teratogenic process. These modifications include alterations to histone proteins, which affect chromatin structure and gene expression without changing the underlying DNA sequence. One such modification is histone hyperacetylation, which can lead to aberrant gene activation or repression, disrupting normal developmental processes. Histone modifications are particularly significant because they can have long-term effects on gene expression across generations, potentially increasing the susceptibility of offspring to teratogenic effects in the future (López- Rodríguez et al., 2018). The ability of certain teratogens to induce such epigenetic changes highlights the complexity of developmental toxicity and the need for further research into the molecular pathways that govern these processes.



Figure 2: Mechanisms of Teratogenicity:

This figure demonstrates the interplay between oxidative stress and epigenetic changes, leading to developmental abnormalities. These factors collectively contribute to teratogenic effects during fetal development.

The timing of teratogenic exposure plays a critical role in the manifestation of birth defects. Certain stages of embryonic and fetal development are particularly sensitive to the effects of teratogens, and exposure during these stages can lead to significant developmental disruptions. Organogenesis, the phase in which the major organs of the body are forming, is a period of heightened vulnerability. This occurs primarily during the first trimester of pregnancy, when the basic structures of the heart, brain, limbs, and other vital organs are being established. Disruptions during this critical period can lead to structural malformations, such as congenital

heart defects and limb abnormalities. Schmid (2006) notes that any disruption in this stage can have profound consequences, as the organs being formed are essential for the long-term health and functionality of the fetus.

The developmental stage at the time of exposure is thus of utmost importance in determining the type and severity of the teratogenic effects. Studies conducted on rodents and rabbits have demonstrated how teratogens can affect different organs depending on the time of exposure during pregnancy. For example, exposure to thalidomide during the organogenesis phase in rabbits leads to limb malformations, but if the drug is administered later in gestation, the effects are less pronounced (Tiboni & Kessel, 2006). Similarly, the timing of exposure to valproic acid is crucial in determining whether neural tube defects will occur. These findings underscore the importance of understanding the critical windows of susceptibility during pregnancy to assess the risks posed by various teratogens accurately.

Table 2: Key Stages of Development Sensitive to Teratogens

Developmental Stage	Critical Period	Drugs/Agents Affecting This Stage	Examples of Developmental Defects
Fertilization & Early Embryogenesis	0-3 weeks	Alcohol, Thalidomide, Anticonvulsants (e.g., Valproic acid)	Neural tube defects, limb malformations, craniofacial abnormalities
Organogenesis	3-8 weeks	Retinoids (e.g., Isotretinoin), ACE inhibitors, Thalidomide	Cardiac malformations, neural tube defects, cleft palate
Neurogenesis	8-16 weeks	Valproic acid, Methotrexate, Cocaine	Intellectual disability, neural tube defects, developmental delays
Fetal Period	16 weeks to birth	Alcohol, Certain antibiotics (e.g., Tetracycline)	Growth retardation, low birth weight, facial dysmorphia
Postnatal Development	Birth to early childhood	Exposure to endocrine disruptors, heavy metals	Learning disabilities, developmental delays

Animal Models for Teratogenicity Testing

The selection of appropriate animal models for teratogenicity testing is a critical factor in understanding the developmental effects of various substances and their potential risks to humans. Several considerations influence the choice of species, including genetic similarity, gestation period, and ethical concerns. Rodents, such as rats and mice, are among the most commonly used models due to their genetic tractability and short gestation periods, which make them ideal for high-throughput screening of potential teratogens. Their genetic makeup is well- documented, and various inbred strains are available for controlled studies, which allows researchers to pinpoint genetic susceptibility factors to teratogenic effects (Vargesson, 2015). However, while rodents provide valuable data on drug toxicity, their developmental processes do not always fully mimic those of humans, particularly in terms of organ development and metabolic pathways.

Rabbits, on the other hand, are frequently used in reproductive toxicity studies because their fetal development more closely resembles that of humans in certain aspects. Rabbit fetuses undergo similar patterns of organogenesis and are more sensitive to teratogenic effects than other rodent species, making them particularly valuable for identifying developmental malformations caused by external substances. This makes them especially important for testing substances that may affect limb development, as seen in thalidomide-induced limb defects (Tiboni et al., 2006).

When seeking the most human-relevant models, non-human primates (such as macaques and baboons) are considered the gold standard for assessing the human-like response to teratogens due to their physiological and genetic similarities to humans. Although their gestation periods are significantly longer than those of rodents and rabbits, their use provides the most accurate depiction of the potential risks posed by teratogens to human pregnancies (Gilbert-Barness, 2008). However, the use of non-human primates is ethically controversial, and such studies are often limited by strict regulations and the high cost of care.

Table 3: Comparison of Animal Models Used in Teratogenicity Testing

Animal Model	Gestation Length	Developmental Similarities	Ethical Considerations	Advantages	Limitations
Rodents (e.g., Mice, Rats)	19-21 days (Mice), 21-23 days (Rats)	High genetic tractability, similar	Ethical concerns related to high	Cost- effective, easy to breed,	Species differences limit

		organogenesis timeline	throughput testing	genetically manipulable	extrapolation to humans
Rabbits	28-32 days	Similar to humans in limb bud development	Ethical concerns with handling and breeding	Sensitive to teratogenic effects, useful for limb defects studies	Shorter gestation period limits long-term studies
Non-Human Primates	165-175 days	Close genetic and developmental similarity to humans	High ethical concerns, expensive, difficult to handle	Closest model to humans, crucial for human- specific studies	High cost, limited availability, ethical challenges

This table compares the major animal models used in teratogenicity testing based on factors such as gestation length, developmental similarities to humans, and ethical concerns, helping to highlight the trade-offs in using each model for specific research objectives.

Advancements in modern technology have significantly enhanced the efficiency and accuracy of teratogenicity testing, particularly with the integration of artificial intelligence (AI) and machine learning in analyzing teratogenic data. These technologies enable the rapid screening of large numbers of compounds for their potential to cause developmental abnormalities in animal models. By processing vast amounts of data, AI algorithms can identify patterns that might not be immediately apparent to researchers, thus improving the predictive accuracy of teratogenicity tests. Furthermore, AI can assist in analyzing multi-species data, allowing for a more comprehensive understanding of how different species respond to the same teratogens. This is crucial because it facilitates the identification of teratogenic risks across various animal models, which can then be extrapolated to human health risks. Baker et al. (2020) discuss how these technologies are transforming the field of teratogenicity testing, making it faster and more effective while reducing the reliance on animal testing.

By combining traditional animal studies with cutting-edge computational techniques, researchers can now predict the potential teratogenicity of substances with greater precision, ultimately

streamlining the drug development process and improving safety assessments for pregnant women and their unborn children.

Animal models have played a fundamental role in identifying the teratogenic effects of a wide range of substances, providing critical data that inform public health guidelines and regulatory decisions. Thalidomide, for example, is one of the most well-documented teratogens, with extensive studies conducted in rabbits and other animals demonstrating its ability to disrupt limb bud development and cause severe congenital malformations. In particular, studies in rabbits have shown that thalidomide exposure during early pregnancy can result in phocomelia, a condition characterized by limb reductions (Vargesson, 2015). This finding was crucial in understanding how the drug caused birth defects in humans, leading to regulatory reforms in drug testing and safety measures.

Similarly, valproic acid, an anticonvulsant drug used to treat epilepsy, has been shown to cause neural tube defects in rodents exposed to the drug during pregnancy. Research conducted on mice revealed that valproic acid interferes with normal neural tube closure, leading to defects such as spina bifida and anencephaly (Wells et al., 2005). These findings have been essential in establishing the drug's teratogenic potential and informing its usage guidelines for pregnant women. Additionally, the retinoid drug isotretinoin, used in the treatment of acne, has been found to cause a range of craniofacial and neurological defects in animal models, leading to stringent warnings regarding its use during pregnancy (Tiboni & Kessel, 2006).

These examples highlight the critical role of animal studies in providing the initial data needed to understand the teratogenic potential of drugs and chemicals, ultimately shaping public health policies and drug safety guidelines.

Translating Animal Study Findings to Human Health

While animal models are invaluable tools for studying teratogenicity, it is essential to recognize that these models do not always perfectly predict human outcomes. Species-specific variations in key biological processes, such as drug metabolism, placental function, and teratogenic susceptibility, can lead to differences in how animals and humans respond to the same teratogenic exposures. These variations pose a challenge when attempting to directly translate

indings from animal studies to human health implications (Polifka & Friedman, 2007). For instance, differences in the expression of enzymes responsible for drug metabolism may result in distinct pharmacokinetics between species, which in turn affects the distribution of drugs in the fetal system. Additionally, while some animals exhibit remarkable similarities to humans in terms of developmental processes, others may have significant biological differences that limit the relevance of their findings.

However, non-human primates are often considered the most reliable models for studying human teratogenicity due to their close genetic and physiological similarities to humans. Non-human primates share many characteristics with humans in terms of fetal development, making them particularly useful for predicting human teratogenic outcomes. Studies on non-human primates have provided valuable data regarding the developmental effects of drugs like thalidomide, valproic acid, and isotretinoin, offering more accurate representations of how these substances may affect human pregnancies (King et al., 2000). Nevertheless, while these models are the best available option for studying teratogenicity in humans, ethical considerations and the high cost of using primates limit their widespread use, making it essential to continuously improve and refine animal testing methodologies.

Figure 3: Comparative Development of Embryos in Humans and Non-Human Primates



illustrates the developmental timelines of embryos in both species, highlighting key stages fromfertilization to the neonatal period. It emphasizes the similarities and differences in developmental processes and their vulnerability to teratogenic exposure.

Findings derived from animal models have played a pivotal role in shaping human health regulations and safety guidelines for drug use during pregnancy. The thalidomide tragedy is a prime example of how animal studies can directly influence public health policy. When thalidomide was found to cause severe limb malformations and other developmental defects in infants, animal studies provided critical insights into how the drug disrupted limb bud development in rabbits and other species. These studies led to the creation of strict regulatory guidelines for the approval of drugs during pregnancy and set new standards for reproductive toxicity testing (Polifka & Friedman, 2007). In the wake of the thalidomide disaster, regulatory agencies such as the FDA and EMA established more stringent requirements for preclinical testing of drugs in animal models to ensure their safety during pregnancy.

Similarly, valproic acid, a widely used anticonvulsant, has prompted significant concern due to its teratogenic effects, particularly its association with neural tube defects in humans. Animal studies in rodents, which showed that valproic acid interferes with the normal closure of the neural tube, led to increased awareness of the risks associated with its use during pregnancy. As a result, warnings about valproic acid's teratogenic potential have been included in regulatory guidelines, and healthcare providers are now more cautious when prescribing this drug to pregnant women (Polifka & Friedman, 2007). In both cases, animal model studies provided the foundational evidence needed to inform regulatory policies aimed at reducing the risk of teratogenic effects in human populations.

Table 4: Key Human Teratogenic Events and Animal Study Contributions

Teratogenic Event	Teratogen/Drug	Key Findings in Animal Studies	Human Health Impact	Regulatory Changes
Thalidomide Embryopathy	Thalidomide	Animal studies in rabbits and rodents showed limb malformations (phocomelia) and organ defects.	Thalidomide caused severe birth defects, particularly limb malformations in thousands of infants.	Thalidomide was banned for use during pregnancy, with regulatory guidelines established for drug safety in pregnancy.
Neural Tube Defects	Valproic acid	Animal studies showed neural tube defects, craniofacial malformations, and developmental delays in rodents.	Exposure to valproic acid during pregnancy is associated with an increased risk of neural tube defects and other craniofacial abnormalities in humans.	Warnings issued about valproic acid use during pregnancy, with recommendations for alternative medications for pregnant women.
Cleft Lip and Palate	Isotretinoin (Accutane)	Studies in rodents and rabbits showed facial clefts and other craniofacial abnormalities following isotretinoin exposure.	Isotretinoin was linked to a high incidence of cleft lip and palate, as well as other severe malformations in human embryos.	Strict guidelines and risk management programs established, including the mandatory use of contraceptives during treatment and prohibition during pregnancy.
Fetal Alcohol Syndrome (FAS)	Alcohol	Animal models demonstrated that alcohol exposure during pregnancy causes craniofacial abnormalities, growth retardation, and brain defects.	In humans, prenatal alcohol exposure leads to FAS, characterized by facial abnormalities, developmental delays, and intellectual disabilities.	Increased public health awareness, research funding for FAS prevention, and updated guidelines on alcohol consumption during pregnancy.

Congenital Heart Defects	ACE Inhibitors (e.g., Enalapril)	Animal studies in rats showed developmental abnormalities in the heart and kidneys of fetuses exposed to ACE inhibitors.	ACE inhibitors during pregnancy can lead to congenital heart defects, renal anomalies, and developmental delay in humans.	Warnings about the use of ACE inhibitors in pregnancy, with guidelines recommending alternatives for managing hypertension in pregnant women.

This table summarizes major teratogenic events, the role of animal studies in identifying these risks, and the subsequent regulatory changes that have been implemented to protect human health. Each event is tied to specific findings in animal models, which led to significant regulatory actions to prevent similar outcomes in human populations.

Factors Influencing Teratogenicity in Humans

For a drug to exert teratogenic effects on a developing fetus, it must be able to cross the placenta and reach the fetus in sufficient concentrations. The placental barrier is a critical determinant in the transfer of substances from the maternal circulation to the fetal environment. This transfer is influenced by several factors, including lipid solubility, molecular weight, and protein binding. Drugs that are more lipid-soluble tend to cross the placenta more easily because they can diffuse across the lipid-rich membranes of the placental cells. Similarly, low molecular weight substances (typically less than 500 Daltons) are more likely to pass through the placenta, whereas larger molecules have more difficulty crossing into the fetal circulation (Koren et al., 2017). Another important factor is protein binding; drugs that are highly bound to maternal proteins, such as albumin, may not cross the placenta as easily as those that remain unbound.

Certain substances, like thalidomide and alcohol, can easily cross the placental barrier due to their lipophilic nature and low molecular weight. Thalidomide, once widely prescribed as a sedative and anti-nausea medication, demonstrated its teratogenic effects by crossing the placental barrier and affecting fetal limb development, leading to phocomelia and other severe malformations (Vargesson, 2015). Similarly, alcohol is a well-known teratogen that can cross the placenta and disrupt fetal development, particularly during the early stages of pregnancy, leading to fetal alcohol spectrum disorders (FASD). The ability of these substances to cross the placental barrier and interfere with fetal development underscores the importance of understanding the pharmacokinetics of drugs during pregnancy and the need for careful consideration when prescribing medications to pregnant women.



Figure 4: Placental Transfer of Teratogens :

Illustrates how different drugs cross the placenta based on their physical and chemical properties. It shows how factors like molecular weight, lipophilicity, and hydrophilicity influence the transfer of substances from maternal to fetal circulation, with smaller, more lipophilic drugs crossing more easily than larger, hydrophilic molecules.

The teratogenic potential of a substance is not solely determined by the characteristics of the substance itself; genetic and environmental factors also play a significant role in influencing the risk of developmental toxicity. The genetic makeup of the fetus can significantly affect its susceptibility to teratogenic effects. Certain genetic variations may make the developing fetus more or less sensitive to the effects of teratogens, influencing factors such as the metabolism of drugs, the ability of cells to repair DNA damage, and the functioning of key signaling pathways involved in development. For example, genetic polymorphisms in enzymes involved in drug metabolism, such as cytochrome P450 enzymes, may lead to variations in how substances like valproic acid or alcohol are processed, ultimately affecting the degree of teratogenic damageIn addition to genetic factors, environmental influences can also modulate the teratogenic effects of certain substances. Exposure to endocrine disruptors—chemicals that interfere with hormonal signaling—has been shown to enhance the teratogenic effects of various drugs. Substances such as bisphenol A (BPA) and phthalates can disrupt normal hormone signaling during critical periods of fetal development, potentially increasing the risk of malformations when combined with other teratogens (López-Rodríguez et al., 2018). Environmental factors, such as diet, exposure to pollution, and stress, may also alter the way the body responds to teratogens, either enhancing or mitigating their effects. For instance, maternal malnutrition or exposure to toxic chemicals in the environment may compromise the body's ability to detoxify harmful substances, thereby increasing the risk of developmental defects.

Table 5: Genetic and Environmental Factors Influencing Teratogenicity

Factor Type	**Specific Factors**	**Influence on Teratogenic Susceptibility**	**Examples of Associated Teratogenic Effects**
Genetic Variants	P450 enzyme polymorphisms (e.g., CYP1A1, CYP2D6)	Variations in enzyme activity can affect drug metabolism, leading to altered exposure to teratogens.	Altered response to medications like anticonvulsants, leading to congenital malformations.
Maternal Health Conditions	Diabetes, Obesity, Hypertension	These conditions can increase the risk of teratogenic effects due to altered placental function or metabolic changes.	Neural tube defects, congenital heart defects, low birth weight.
Endocrine Disruptors	Bisphenol A (BPA), Phthalates, DDT	Environmental chemicals that interfere with hormone regulation, leading to developmental defects.	Cleft palate, genital abnormalities, neurodevelopmental disorders.
Maternal Age	Advanced maternal age (>35 years)	Older maternal age increases the risk of chromosomal abnormalities and may influence drug metabolism.	Down syndrome, neural tube defects, heart defects.

Nutritional Factors	Folic acid deficiency, vitamin A excess	Deficiencies or excesses in nutrients during pregnancy can disrupt normal fetal development.	Spina bifida (folic acid deficiency), craniofacial malformations (vitamin A excess).
Maternal Exposure to Infections	Cytomegalovirus, Rubella, Zika virus	Infections during pregnancy can increase the risk of teratogenic effects due to direct infection of fetal tissues.	Microcephaly, congenital heart defects, hearing loss.
Environmental Exposures	Air pollution, Pesticides, Lead exposure	Environmental toxins can interfere with fetal development, often via oxidative stress or immune modulation.	Low birth weight, cognitive delays, developmental disorders.

This table outlines specific **genetic** and **environmental factors** that can influence susceptibility to teratogens. Variations in **enzyme function**, maternal **health conditions**, and **exposure to environmental toxins** can all significantly affect the likelihood of developmental defects during pregnancy.

Future Directions and Research Challenges

The field of teratogenicity research is rapidly evolving, thanks to groundbreaking technologies that are providing new insights into the molecular and genetic mechanisms behind developmental toxicity. One of the most transformative innovations is CRISPR gene-editing technology, which allows researchers to modify specific genes in animal models, providing a more precise understanding of how certain genes may influence susceptibility to teratogens. CRISPR has enabled scientists to investigate the effects of gene mutations on fetal development and better understand the genetic basis of teratogenic effects (Baker et al., 2020). This technology offers an unprecedented ability to create humanized animal models that more closely resemble human genetic and developmental processes, improving the accuracy of predictions regarding how teratogens might affect humans.

Another promising field is nanotechnology, which has the potential to revolutionize our understanding of how nanoparticles and other nanoscale materials interact with the developing fetus. Nanoparticles, due to their small size and unique properties, may cross the placenta and influence fetal development in ways that larger molecules cannot. Research into the teratogenic potential of nanomaterials is still in its early stages, but as nanotechnology continues to advance, it could provide valuable information about the safety of materials used in consumer products, pharmaceuticals, and medical devices (Baker et al., 2020). These emerging technologies not only enhance our ability to study teratogenesis at the genetic and molecular levels, but they also offer new avenues for developing more human-relevant models for testing teratogenicity, which could ultimately reduce the need for traditional animal testing.

While animal models have been indispensable in teratogenicity testing, there is growing concern about the ethical implications of using animals in research. As a result, there is a concerted effort within the scientific community to reduce the reliance on animal testing and develop more predictive, human-relevant models for studying teratogens. Recent advancements in artificial intelligence (AI) and bioinformatics are opening up new possibilities for teratogenicity screening that could significantly decrease the need for animal experimentation. AI-driven platforms, for instance, can analyze vast amounts of biological data, identifying patterns and making predictions about the teratogenic potential of substances based on in silico models. These models can be used to predict how various chemicals might affect human development, offering a more efficient and cost-effective way to screen potential teratogens.

Organ-on-chip systems represent another promising innovation. These devices use microfluidic technology to simulate the physiological environment of human organs, including the placenta and developing fetus. By mimicking the interactions between different tissues and systems, organ-on-chip platforms provide a more accurate representation of human development than traditional animal models. These systems can be used to study the effects of teratogens on human fetal development in a way that is both ethically sound and scientifically relevant (Koren et al., 2017). As these technologies continue to evolve, they may serve as powerful alternatives to animal testing, enhancing the predictive accuracy of

teratogenicity assessments while minimizing ethical concerns.

2. CONCLUSION

This paper has explored the critical role that animal models play in advancing our understanding of teratogenesis and its implications for human health. Animal studies have been essential in identifying the molecular mechanisms behind teratogenic effects, such as oxidative stress and epigenetic modifications, which can disrupt fetal development. Rodents, rabbits, and non-human primates have each contributed valuable insights into how drugs and environmental exposures can cause congenital malformations, from limb deformities to neural tube defects. However, while these models have proven to be indispensable for testing potential teratogens, they are not without limitations. Differences in genetic makeup, drug metabolism, and developmental processes between species can complicate the extrapolation of findings to humans, making it essential to refine current testing methods and explore alternatives. As highlighted throughout the paper, the field of teratogenicity research faces challenges, particularly in terms of ethical considerations and the need for human-relevant models. These challenges have led to the exploration of emerging technologies that can offer more precise and ethical alternatives to traditional animal testing.

The future of teratogenicity research is increasingly shifting towards the development and implementation of non-animal models. Technologies like CRISPR gene-editing, nanotechnology, and organ-on-chip systems hold immense potential for providing more accurate and human-relevant models of fetal development, thereby enhancing our ability to predict the teratogenic effects of substances. These technologies not only promise to improve predictive accuracy but also offer the possibility of reducing the reliance on animal testing, aligning with ethical standards while advancing scientific knowledge. Additionally, artificial intelligence (AI) and bioinformatics have the capacity to analyze large datasets more efficiently, providing faster and more reliable results in the assessment of teratogenic risks. By incorporating these cutting- edge technologies into research, we can achieve a more holistic and ethical approach to studying teratogenesis. The continued evolution of these tools will likely lead to better safety assessments, ultimately improving human health outcomes and minimizing the risk of developmental disorders caused by teratogenic substances.

REFERENCES

1. Wilson, J. G. (1977). Current status of teratology: General principles and mechanisms derived from animal studies. In J. G. Wilson & F. C. Fraser (Eds.), Handbook of Teratology (pp. 147–174). Plenum Press.
2. Szyf, M. (1985). Cell cycle-dependent regulation of eukaryotic DNA methylase level.
3. Journal of Biological Chemistry, 260(25), 13933–13939.
4. King, C., Rios, G., Green, M., & Tephly, T. (2000). UDP-glucuronosyltransferases.
5. Current Drug Metabolism, 1(2), 143–161.
6. Grandjean, P., & Landrigan, P. J. (2006). Developmental neurotoxicity of industrial chemicals. Lancet, 368(9553), 2167–2178.
7. Menegola, E., Di Renzo, F., & Vargesson, N. (2006). Postulated pathogenic pathways in triazole fungicide dysmorphogenic effects. Reproductive Toxicology, 22(2), 121–130.
8. Polifka, J. E., & Friedman, J. M. (2007). Clinical teratology: Identifying teratogenic risks in humans. Clinical Genetics, 56(6), 409–420.
9. Di Renzo, F., Menegola, E., & Di Giulio, C. (2007). Relationship between embryonic histonic hyperacetylation and axial skeletal defects in mice exposed to the three HDAC inhibitors apicidin, MS-275, and sodium butyrate. Toxicological Sciences, 97(1), 39–50.
10. Frias, J. L., & Gilbert-Barness, E. (2008). Human teratogens: Current controversies.
11. Advances in Pediatrics, 55, 171–211.
12. Gilbert-Barness, E. (2008). Human teratogens: Current controversies. Advances in Pediatrics, 55, 171–211.
13. Buhimschi, C. S., & Weiner, C. P. (2009). Medications in pregnancy and lactation: Part
14. 2. Drugs with minimal or unknown human teratogenic effect. Obstetrics and Gynecology Clinics of North America, 31(2), 963–979.
15. Wells, P. G., McCallum, G. P., Chen, C. S., et al. (1997). Oxidative damage in chemical teratogenesis. Mutation Research, 414(1), 1–14.
16. Wells, P. G., McCallum, G. P., Chen, C. S., et al. (2005). Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicology and Applied Pharmacology, 207(2), 300–314.
17. Tiboni, G. M., & Kessel, M. (2006). Defining critical periods for itraconazole-induced cleft palate, limb defects, and axial skeletal malformations in the mouse. Toxicology Letters, 164(3), 308–319.

18. Vargesson, N. (2015). Thalidomide induced teratogenesis: History and mechanisms.
19. Birth Defects Research (Part C), 105(2), 140–156.
20. Koren, G., et al. (2017). Pharmacokinetics of drugs in pregnancy: Understanding placental transfer and metabolism. Reproductive Toxicology, 71, 55–62.
21. López-Rodríguez, D., et al. (2018). Maternal and fetal genetic and environmental factors influencing the susceptibility to teratogenicity. Reproductive Toxicology, 78, 184–190.
22. Baker, S. G., et al. (2020). Advances in human-specific models for developmental toxicity testing. Toxicology and Applied Pharmacology, 387, 114801.
23. Ingber, D. E. (2022). Human organs-on-chips for disease modelling, drug development and personalized medicine. Nature Reviews Genetics.
24. Li, X., Wang, H., You, X., & Zhao, G. (2025). Organoids-on-Chips Technology: Unveiling New Perspectives in Rare-Disease Research. International Journal of Molecular Sciences, 26(9), 4367.
25. [Frontiers Review]. (2024). In silico modelling of organ-on-chips: An overview.
26. Frontiers in Bioengineering and Biotechnology.
27. U.S. Government Accountability Office. (2025). Human organ-on-a-chip technologies: Benefits and current limitations. GAO Report.
28. [ScienceDirect]. (2025). AI-powered OoC and Digital Twin models to reduce animal testing. Drug Discovery Today, 30(2), 123–137